Myriad Genetics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Samraat S Raha
- Full Time Employees
- 2,700
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 322 North 2200 West Salt Lake City UT United States 84116
- IPO Date
- Oct 6, 1995
- CIK
- 0000899923
- Website
- myriad.com
- Similar Companies
- Business
- Myriad Genetics, Inc. (MYGN) operates as a leading molecular diagnostic testing and precision medicine company focused on hereditary cancer, reproductive health, oncology, urology, and mental health genetic testing; its core products include the myRisk Hereditary Cancer Test assessing risk for 11 major cancers across 63 genes, Prequel Prenatal Screen for chromosomal abnormalities like trisomies 21, 18, and 13, Foresight Carrier Screen for over 270 inherited conditions, GeneSight Psychotropic Test covering 61 medications for depression, anxiety, and ADHD, and Precise Oncology solutions such as molecular residual disease testing. Founded in 1991 and headquartered in Salt Lake City, Utah, the company employs proprietary technologies to analyze biological samples like blood or saliva, providing physicians and patients with actionable insights for disease risk prediction, treatment guidance, and progression assessment across the United States and internationally. Recent developments include a September 2025 strategic collaboration with SOPHiA GENETICS to develop companion diagnostics for liquid biopsy-based therapy selection, partnerships with GlaxoSmithKline for HRD testing in ovarian cancer, QIAGEN for distributable HRD tests, National Cancer Center Hospital East in Japan for molecular residual disease studies, PATHOMIQ for AI-enabled prostate cancer testing, and Clairity with MagView for an integrated AI-genetic risk platform in breast health; additionally, the company expanded its MyRisk panel, launched FirstGene combined prenatal screening, secured a $200 million senior secured term loan from OrbiMed in 2025 to support growth, and reported oncology volume increases alongside Q3 2025 financial results emphasizing product launches and commercial investments.
Company News
Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates
Myriad Genetics Q3 Earnings Call Highlights
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Applied Dna Sciences (NASDAQ:BNBX) and Myriad Genetics (NASDAQ:MYGN) Head to Head Analysis
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)